Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Portia Shea"'
Publikováno v:
Clin Infect Dis
Background Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs
Autor:
Ruthanne Marcus, Lynn M. Madden, Alexei Zelenev, Julia Rozanova, Alyona Mazhnaya, Portia Shea, Frederick L. Altice
Publikováno v:
Drug and alcohol dependence. 190
Background Opioid agonist therapies (OAT) in Ukraine were first introduced in 2004 not as addiction treatment, but for HIV prevention. Numerous obstacles have thwarted OAT scale-up, including individual constraints and structural barriers. Methods A
Autor:
Ruthanne Marcus, Anna Meteliuk, Tatiana Prokhorova, Alyona Mazhnaya, Iryna Pykalo, Tatiana Fomenko, Frederick L. Altice, Portia Shea, Alexei Zelenev
Publikováno v:
Int J Drug Policy
Background Ukraine, a country of 45.5 million people, has one of the most volatile HIV and HCV epidemics in the world. In this paper, we estimate the prevalence of HIV and HCV among PWID in five Ukrainian cities. Methods A cross-sectional study was c
Publikováno v:
Open Forum Infectious Diseases
Background It is estimated that 1,295 per 100,000 are people living with HIV (PLWH) in New Haven, which is the second highest rate of HIV prevalence in Connecticut. Since 2009, New Haven has established the Ryan White (RW) HIV Care Continuum. The mai